Axitinib

Generic Name: Axitinib

Brand Names: Inlyta, Axitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈N_₄OS

CAS Number: 319460-85-0

Unique Ingredient Identifier: C9LVQ0YUXG

Background: Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...

Indication: Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Thyroid cancer

Associated Therapies: First Line Chemotherapy

Clinical Trials

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Phase 2

Completed

Conditions: Stage IV Prostate Cancer
Stage III Prostate Cancer

Interventions: Procedure: therapeutic conventional surgery
Drug: axitinib
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis

First Posted Date: 2011-06-29

Last Posted Date: 2023-03-07

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 11

Registration Number: NCT01385059

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Axitinib

First Posted Date: 2011-05-12

Last Posted Date: 2018-06-20

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 50

Registration Number: NCT01352728

Locations: 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Phase 2

Completed

Conditions: Stage IIIA Melanoma
Melanoma
Malignant Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma

Interventions: Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Drug: Axitinib
Other: pharmacological study

First Posted Date: 2011-03-23

Last Posted Date: 2021-01-20

Lead Sponsor: University of California, Irvine

Target Recruit Count: 11

Registration Number: NCT01321437

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Axitinib

First Posted Date: 2010-12-21

Last Posted Date: 2024-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT01263769

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

Phase 2

Completed

Conditions: Adrenal Cortex Neoplasms

Interventions: Drug: Axitinib

First Posted Date: 2010-12-07

Last Posted Date: 2013-06-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT01255137

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Nasopharyngeal Carcinoma (NPC) Axitinib

Phase 2

Completed

Conditions: Recurrent or Metastatic NPC

Interventions: Drug: axitinib

First Posted Date: 2010-11-30

Last Posted Date: 2017-04-25

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 37

Registration Number: NCT01249547

Locations: 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Axitinib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-08-03

Last Posted Date: 2018-06-08

Lead Sponsor: Adil Daud

Target Recruit Count: 40

Registration Number: NCT01174238

Locations: 🇺🇸
Cutaneous Onocology Group at the Helen Dillar Family Comprehensive Cancer Center UCSF, San Francisco, California, United States

A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Axitinib

First Posted Date: 2010-06-09

Last Posted Date: 2021-03-18

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 145

Registration Number: NCT01140737

Locations: 🇬🇧
Western General Hospital, Edinburgh, Scotland, United Kingdom
🇬🇧
Christies, Manchester, United Kingdom
🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom

and more 10 locations

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Advanced Gastric Cancer
Stomach Neoplasms

Interventions: Drug: axitinib
Drug: capecitabine
Drug: cisplatin

First Posted Date: 2009-02-12

Last Posted Date: 2013-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00842244

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: axitinib

First Posted Date: 2009-02-04

Last Posted Date: 2017-05-30

Lead Sponsor: Pfizer

Target Recruit Count: 213

Registration Number: NCT00835978

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 60 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy